Context Therapeutics (NASDAQ:CNTX) Rating Increased to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Context Therapeutics from sell to hold, adding to a mixed but generally positive analyst backdrop for the stock.
• The company reported its latest quarterly results with EPS of -$0.09, beating the consensus estimate of -$0.12 by $0.03. Analysts expect Context Therapeutics to post -0.49 EPS for the full year.
• Shares were up 2.1% and opened at $2.38, while institutional ownership remains notable at 14.03% of shares outstanding.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.

Other analysts have also issued research reports about the company. Lifesci Capital upgraded Context Therapeutics to a "strong-buy" rating in a report on Monday, February 23rd. Guggenheim reiterated a "buy" rating and set a $5.00 price objective on shares of Context Therapeutics in a report on Tuesday, March 24th. D. Boral Capital reiterated a "buy" rating and set a $9.00 price objective on shares of Context Therapeutics in a report on Tuesday, March 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Context Therapeutics in a report on Monday, April 20th. Finally, Piper Sandler increased their price objective on Context Therapeutics from $4.00 to $7.00 and gave the company an "overweight" rating in a report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $6.60.

Context Therapeutics Trading Up 2.1%

Shares of NASDAQ:CNTX opened at $2.38 on Friday. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $3.62. The business's fifty day simple moving average is $2.62 and its 200-day simple moving average is $1.90. The company has a market capitalization of $218.67 million, a PE ratio of -5.67 and a beta of 1.57.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03. Research analysts predict that Context Therapeutics will post -0.49 EPS for the current year.

Hedge Funds Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd raised its stake in Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company's stock worth $149,000 after acquiring an additional 91,008 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Context Therapeutics during the 4th quarter valued at about $3,824,000. Marshall Wace LLP raised its stake in shares of Context Therapeutics by 7,153.7% during the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company's stock valued at $3,812,000 after buying an additional 2,557,448 shares during the last quarter. State Street Corp raised its stake in shares of Context Therapeutics by 8.5% during the 4th quarter. State Street Corp now owns 165,607 shares of the company's stock valued at $243,000 after buying an additional 13,000 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Context Therapeutics by 58.8% during the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company's stock valued at $747,000 after buying an additional 188,202 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company's stock.

Context Therapeutics Company Profile

Context Therapeutics NASDAQ: CNTX is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company's research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.